港股早評:三大指數低開 汽車股跌幅明顯 中醫藥股大漲
隔夜美股三大指數小幅收跌,中概指數大跌3.84%。港股三大指數低開,恆指跌0.46%,國指跌0.44%,恆生科技指數跌0.64%。盤面上,大型科技股跌多漲少,百度跌近2%,快手、阿里巴巴跌1.4%,騰訊、網易飄綠,京東、美團、小米小幅上漲;DeepSeek概念股、汽車股跌幅明顯,金山雲跌6%,北京汽車大跌超8%,小鵬汽車跌3.2%,昨日創歷史新高的比亞迪股份跌2.64%;影視娛樂股、快遞股、香港本地銀行股、電力股多數走低。另一方面,生物醫藥走強,中醫藥股大漲,中國中藥高開8%,同仁堂國藥漲4.64%,固生堂漲3.45%,腦機接口概念股走高,微創腦科學漲近7%,南京熊貓電子漲超3%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.